With 50% of the "no hopers" responded to cavatak with yervoy in the latest results I can't imagine Bristol Myers not being interested, especially as yervoy is faltering.
But Merck must be interested too to make their extremely valuable asset keytruda safer and more potent.
Here is a bit from the US's endpoint news:
Small biotech — big ambitions. Viralytics’ oncolytics therapy makes the showcase round at #AACR17 with positive combo snapshot
WASHINGTON, DC — When you talk to Viralytics CEO Malcolm McColl, he has a habit of reminding his listeners about just how small his public Australian biotech is. Small staff, small studies. And there are just so many things a small biotech can do.
Malcolm McColl
But he and his company {ASX: VLA} have some very big ambitions in the hot oncolytics field, building their hopes around a therapy called Coxsackievirus A21 (or CVA21 or Cavatak). And today the powers that be at AACR are steering their latest data into the showcase morning round.
At the time of the data cutoff for AACR, the company had evaluable responses from 22 patients in a small melanoma study combining their therapy — using a nongenetically altered cold virus to infect cancer cells, designed to destroy them and recruit T cells for a followup attack — with Yervoy.
https://endpts.com/small-biotech-bi...round-at-aacr17-with-positive-combo-snapshot/
